by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, Clinical Pharmacy Specialist in the Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD...
by Alex Kadhim
A recent study published in The Lancet Haematology has demonstrated that patients with aggressive B-cell lymphomas experience a substantial burden of symptoms shortly after CAR T-cell infusion,...
by Alex Kadhim
Researchers at the University of Pennsylvania have found that CAR T-cell therapy response in recurrent glioblastoma (GBM) is affected by divergent remodeling of the immune system.
by ASTCT Talks and Oncology on the Go
This ASTCT and CancerNetwork® collaboration recaps key hematologic oncology advances from the 2026 ASCO Annual Meeting, featuring expert discussion from a live X Spaces session. Highlights...
by Alex Kadhim
Researchers from the University of Lausanne and University Hospital of Zurich in Switzerland demonstrate that PD‑1–targeted CAR‑T cells can selectively reduce HIV reservoir cells and delay...
by Alex Kadhim
Researchers from leading institutions in Shanghai, China, identified a key immune signature driving steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD), involving expanded CD28+ CD8+...